Citations

Clear

9383 citation(s) found for "Thomas, PS".

Treatment of vitamin D deficiency in children
Johnson, Casey R. , Leopold, Kaitlin N., Thacher, Thomas D., Fischer, Philip R. , Leopold, Kaitlin , Thacher, Thomas D.

Mayo Clinic

Expert Review of Endocrinology & Metabolism | October 11, 2023 | Volume: 18 | Issue: 6 | Pages: 489-502

10.1080/17446651.2023.2270053 | PMID 37861060 Get It

Promoting Inclusive Cancer Care: Beyond Medical Interpreters
Thomas, Alex G. , Porter, Alyx B.

Mayo Clinic

The Oncologist | October 11, 2023 | Volume: 28 | Issue: 12 | Pages: e1131-e1133

10.1093/oncolo/oyad290 | PMID 37861112 Get It

Opportunities exist to promote inclusive cancer care and clinical research to reduce disparity and achieve health equity. Through raising awareness of the nuances of the clinical encounter to promote inclusivity as well as reducing barriers to access and enrollment in clinical trials, a more complete understanding regarding the spectrum of disease and opportunity for inclusive cancer care can be achieved.
EP212 Ilioinguinal Block with Liposomal Bupivacaine for Lower Extremities Revascularization: Have We Found the ‘Right’ Block?
Gurrieri, Carmelina , Almhanni, Ghaith , Sen, Indrani , Carmody, Thomas , Beckermann, Jason , Calvin, Andrew D. , Carmody, Thomas, Tallarita, Tiziano

Mayo Clinic

ePoster session 6 – Station 6 | October 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: A155.3-A156

10.1136/rapm-2023-esra.272 Get It

Biomarkers of cellular senescence and risk of death in humans
Weston, Susan A., Atkinson, Elizabeth J. , Gree, Michaela E. Mc, White, Thomas A. , Heeren, Amanda A., Rocca, Walter A. , Palmer, Allyson K. , Cummings, Steven R. , Fielding, Roger A. , St Sauver, Jennifer L , Mc Gree, Michaela E, Palmer, Allyson K , Bielinski, Suzette J. , LeBrasseur, Nathan K , Sauver, Jennifer L. St. , Mielke, Michelle M. , Olson, Janet E. , LeBrasseur, Nathan K.

Mayo Clinic

Aging Cell | October 8, 2023 | Volume: 22 | Issue: 12 | Pages: No page available

10.1111/acel.14006 | PMID 37803875 Get It

AbstractA robust and heterogenous secretory phenotype is a core feature of most senescent cells. In addition to mediators of age‐related pathology, components of the senescence associated secretory phenotype (SASP) have been studied as biomarkers of senescent cell burden and, in turn, biological age. Therefore, we hypothesized that circulating concentrations of candidate senescence biomarkers, including chemokines, cytokines, matrix remodeling proteins, and growth factors, could predict mortality in older adults. We assessed associations between plasma levels of 28 SASP proteins and risk of mortality over a median follow‐up of 6.3 years in 1923 patients 65 years of age or older with zero or one chronic condition at baseline. Overall, the five senescence biomarkers most strongly associated with an increased risk of death were GDF15, RAGE, VEGFA, PARC, and MMP2, after adjusting for age, sex, race, and the presence of one chronic condition. The combination of biomarkers and clinical and demographic covariates exhibited a significantly higher c‐statistic for risk of death (0.79, 95% confidence interval (CI): 0.76–0.82) than the covariates alone (0.70, CI: 0.67–0.74) (p < 0.001). Collectively, these findings lend further support to biomarkers of cellular senescence as informative predictors of clinically important health outcomes in older adults, including death.
Association Between Whole Blood–Derived Mitochondrial DNA Copy Number, Low‐Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk
Liu, Xue , Sun, Xianbang, Jiang, Wenqing , Lai, M M , Wiggins, Kerri L. , Raffield, Laura M. , Bielak, Lawrence F. , Zhao, Wei , Pitsillides, Achilleas , Haessler, Jeffrey, Blackwell, Thomas W. , Yao, Jie , Qian, Yong , Thyagarajan, Bharat , Peyser, Patricia A. , Heckbert, Susan R. , Seshadri, Sudha , Boerwinkle, Eric , Grove, Megan L. , Larson, Nicholas B. , Smith, Jennifer A. , Fitzpatrick, Annette L., Fornage, Myriam , Ding, Jun , Carson, April P. , Reiner, Alex P. , Hou, Lifang , Wilson, James G. , Rotter, Jerome I. , Bis, Joshua C. , Arking, Dan E. , Zhao, Wei , Wiggins, Kerri L , Raffield, Laura M , Bielak, Lawrence F , Zhao, Wei , Pitsillides, Achilleas , Zheng, Yinan , Yao, Jie , Guo, Xiuqing , Thyagarajan, Bharat , Pankratz, Nathan , Rich, Stephen S , Taylor, Kent D , Peyser, Patricia A , Heckbert, Susan R , Boerwinkle, Eric , Larson, Nicholas B , Smith, Jennifer A , Vasan, Ramachandran S , Fornage, Myriam , Carson, April P , Dupuis, Josée , Reiner, Alexander P , Hou, Lifang , Psaty, Bruce M , Levy, Daniel , Rotter, Jerome I , Bis, Joshua C , Satizabal, Claudia L , Arking, Dan E , Liu, Chunyu , Seshadri, Sudha , Zhang, Yuankai , Zheng, Yinan , Guo, Xiuqing , Pankratz, Nathan , Rich, Stephen S. , Taylor, Kent D. , Vasan, Ramachandran S. , Abecasis, Gonçalo R. , Kooperberg, Charles , Psaty, Bruce M. , Levy, Daniel , Satizábal, Claudia L.

Mayo Clinic

Journal of the American Heart Association | October 7, 2023 | Volume: 12 | Issue: 20 | Pages: No page available

10.1161/jaha.122.029090 | PMID 37804200 Get It

Background The relationship between mitochondrial DNA copy number (mtDNA CN) and cardiovascular disease remains elusive. Methods and Results We performed cross‐sectional and prospective association analyses of blood‐derived mtDNA CN and cardiovascular disease outcomes in 27 316 participants in 8 cohorts of multiple racial and ethnic groups with whole‐genome sequencing. We also performed Mendelian randomization to explore causal relationships of mtDNA CN with coronary heart disease (CHD) and cardiometabolic risk factors (obesity, diabetes, hypertension, and hyperlipidemia). P <0.01 was used for significance. We validated most of the previously reported associations between mtDNA CN and cardiovascular disease outcomes. For example, 1‐SD unit lower level of mtDNA CN was associated with 1.08 (95% CI, 1.04–1.12; P <0.001) times the hazard for developing incident CHD, adjusting for covariates. Mendelian randomization analyses showed no causal effect from a lower level of mtDNA CN to a higher CHD risk (β=0.091; P =0.11) or in the reverse direction (β=−0.012; P =0.076). Additional bidirectional Mendelian randomization analyses revealed that low‐density lipoprotein cholesterol had a causal effect on mtDNA CN (β=−0.084; P <0.001), but the reverse direction was not significant ( P =0.059). No causal associations were observed between mtDNA CN and obesity, diabetes, and hypertension, in either direction. Multivariable Mendelian randomization analyses showed no causal effect of CHD on mtDNA CN, controlling for low‐density lipoprotein cholesterol level ( P =0.52), whereas there was a strong direct causal effect of higher low‐density lipoprotein cholesterol on lower mtDNA CN, adjusting for CHD status (β=−0.092; P <0.001). Conclusions Our findings indicate that high low‐density lipoprotein cholesterol may underlie the complex relationships between mtDNA CN and vascular atherosclerosis.
Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort
Jackson, Trever, Rumbaugh, Malia, Eloyan, Ani , Abreu, Marco , Dage, Jeffrey L. , Snoddy, Casey, Faber, Kelley , Hammers, Dustin B. , Taurone, Alexander, Thangarajah, Maryanne, Aisen, Paul, Kramer, Joel H. , Kukull, Walter A. , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Vemuri, Prashanthi , Day, Gregory S , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Nudelman, Kelly , Foroud, Tatiana , Hammers, Dustin B , Beckett, Laurel , Koeppe, Robert A. , Murray, Melissa E. , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | October 7, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13482 | PMID 37801072 Get It

AbstractIntroductionOne goal of the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) is to investigate the genetic etiology of early onset (40–64 years) cognitive impairment. Toward this goal, LEADS participants are screened for known pathogenic variants.MethodsLEADS amyloid‐positive early‐onset Alzheimer's disease (EOAD) or negative early‐onset non‐AD (EOnonAD) cases were whole exome sequenced (N = 299). Pathogenic variant frequency in APP, PSEN1, PSEN2, GRN, MAPT, and C9ORF72 was assessed for EOAD and EOnonAD. Gene burden testing was performed in cases compared to similar‐age cognitively normal controls in the Parkinson's Progression Markers Initiative (PPMI) study.ResultsPreviously reported pathogenic variants in the six genes were identified in 1.35% of EOAD (3/223) and 6.58% of EOnonAD (5/76). No genes showed enrichment for carriers of rare functional variants in LEADS cases.DiscussionResults suggest that LEADS is enriched for novel genetic causative variants, as previously reported variants are not observed in most cases.Highlights Sequencing identified eight cognitively impaired pathogenic variant carriers. Pathogenic variants were identified in PSEN1, GRN, MAPT, and C9ORF72. Rare variants were not enriched in APP, PSEN1/2, GRN, and MAPT. The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) is a key resource for early‐onset Alzheimer's genetic research
Development and Pilot Testing of a Programmatic System for Competency Assessment in US Anesthesiology Residency Training
Woodworth, Glenn E. , Goldstein, Zachary, Arthur, Mary E. , Bailey, Caryl , Booth, Gregory J , Fromer, Ilana R. , Hallman, Matthew R., Hoang, Thomas, Isaak, Robert S. , Klesius, Lisa L. , Ladlie, Beth L., Mitchell, Sally A. , Juve, Amy K. Miller , McGrath, Brian J., Shepler, John A. , Sims, Charles R. , Spofford, Christina M., Tanaka, Pedro , Maniker, Robert B. , Ambardekar, Aditee P. , Carney, Patricia A. , Chen, Fei , Duncan, Michael J., Mitchell, John

Mayo Clinic

Anesthesia & Analgesia | October 6, 2023 | Volume: 138 | Issue: 5 | Pages: 1081-1093

10.1213/ane.0000000000006667 | PMID 37801598 Get It

BACKGROUND: In 2018, a set of entrustable professional activities (EPAs) and procedural skills assessments were developed for anesthesiology training, but they did not assess all the Accreditation Council for Graduate Medical Education (ACGME) milestones. The aims of this study were to (1) remap the 2018 EPA and procedural skills assessments to the revised ACGME Anesthesiology Milestones 2.0, (2) develop new assessments that combined with the original assessments to create a system of assessment that addresses all level 1 to 4 milestones, and (3) provide evidence for the validity of the assessments. METHODS: Using a modified Delphi process, a panel of anesthesiology education experts remapped the original assessments developed in 2018 to the Anesthesiology Milestones 2.0 and developed new assessments to create a system that assessed all level 1 through 4 milestones. Following a 24-month pilot at 7 institutions, the number of EPA and procedural skill assessments and mean scores were computed at the end of the academic year. Milestone achievement and subcompetency data for assessments from a single institution were compared to scores assigned by the institution’s clinical competency committee (CCC). RESULTS: New assessment development, 2 months of testing and feedback, and revisions resulted in 5 new EPAs, 11 nontechnical skills assessments (NTSAs), and 6 objective structured clinical examinations (OSCEs). Combined with the original 20 EPAs and procedural skills assessments, the new system of assessment addresses 99% of level 1 to 4 Anesthesiology Milestones 2.0. During the 24-month pilot, aggregate mean EPA and procedural skill scores significantly increased with year in training. System subcompetency scores correlated significantly with 15 of 23 (65.2%) corresponding CCC scores at a single institution, but 8 correlations (36.4%) were <30.0, illustrating poor correlation. CONCLUSIONS: A panel of experts developed a set of EPAs, procedural skill assessment, NTSAs, and OSCEs to form a programmatic system of assessment for anesthesiology residency training in the United States. The method used to develop and pilot test the assessments, the progression of assessment scores with time in training, and the correlation of assessment scores with CCC scoring of milestone achievement provide evidence for the validity of the assessments.
Cecal Dieulafoy lesion is a rare cause of lower gastrointestinal bleeding: A case report
Saha, Bibek , Takkellapati, Divya, Beckman, Thomas J.

Mayo Clinic

SAGE Open Medical Case Reports | October 6, 2023 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2050313x231203463 | PMID 37811348 Get It

Dieulafoy lesions are a rare but life-threatening cause of gastrointestinal bleeding. Colonic Dieulafoy lesions are exceptionally rare, comprising only 2% of these lesions. We present a case of cecal Dieulafoy lesion as an unusual cause of lower gastrointestinal bleeding—along with hemoptysis. An 81-year-old male with pulmonary hypertension presented with a one-day history of hematochezia. He subsequently developed new small-volume hemoptysis/hematemesis with increasing oxygen requirements. Bronchoscopy revealed old blood in the left lower lobe, with no active bleeding. The hemoptysis was attributed to severe pulmonary hypertension. Colonoscopy revealed a 2-mm cecal Dieulafoy lesion with spurting bleeding, which was clipped. We report a rare case of cecal Dieulafoy lesion with only 13 other published cases. Our case was complicated by hemoptysis creating an interesting diagnostic dilemma. In patients bleeding from both oral and anal orifices, a brisk upper gastrointestinal bleed—as well as independent causes involving the gastrointestinal and respiratory tracts—should be considered.
FRI137 Histologic And Genetic Characteristics Of Primary Aldosteronism In Late Adulthood
Blinder, Amy, Nanba, Kazutaka , Sapiro, Dina R., Baker, Jessica , Liu, Chia-Jen, Lyden, Melanie L. , Wachtel, Heather , Cohen, Debbie L. , Reincke, Martín , Else, Tobias , Rainey, William E. , Bancos, Irina , Young, William F. , Luther, James Matthew , Williams, Tracy Ann , Giordano, Thomas J. , Udager, Aaron M

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.649 Get It

Abstract Disclosure: A. Blinder: None. K. Nanba: None. D. Sapiro: None. J. Baker: None. C. Liu: None. I. Bancos: None. M. Lyden: None. W. Young: None. H. Wachtel: None. D. Cohen: None. J. Luther: None. T.A. Williams: None. M. Reincke: None. T. Else: None. T.J. Giordano: None. A. Udager: None. W.E. Rainey: None. Background: There is accumulating evidence that changes in adrenal histology and regulation of renin-angiotensin-aldosterone system occur with age. Primary aldosteronism (PA) is the most common cause of endocrine hypertension. Recent clinical studies suggest unique characteristics of PA in elderly patients, including high prevalence of comorbidities and low clinical cure rate after adrenalectomy. However, histologic and genetic features of PA in late adulthood have not been well elucidated. Objective: To determine histologic and genetic characteristics of PA in late adulthood. Methods: Seventy-six patients who underwent unilateral adrenalectomy at the age of 60 or older were included in this study. Formalin-fixed, paraffin-embedded (FFPE) sections of resected adrenal tissue were used for the analysis. Aldosterone synthase (CYP11B2) immunohistochemistry (IHC) was performed to identify the source of inappropriate aldosterone production. Histologic classification was made according to the HISTALDO (histopathology of primary aldosteronism) consensus. CYP11B2 IHC-guided DNA capture followed by sequencing analysis using direct Sanger sequencing or ion torrent based next-generation sequencing (NGS) was performed. Results: Median age of the studied patients was 70 (interquartile range: 64-73). Based on the CYP11B2 IHC, histologic diagnosis was made as follows; aldosterone-producing adenoma (APA, n=23), aldosterone-producing nodule (APN, n=41), and non-functioning adrenocortical adenoma (NFA, n=6). The remaining six cases had multiple CYP11B2-expressing neoplastic lesions, including APA with APN (n=2) and multiple APNs (n=4). Co-existence of NFA with APA or APN(s) was also observed in 13. Sequencing analysis revealed that somatic KCNJ5 mutation was the most frequent genetic alteration in APA (7/23, 30%), whereas somatic CACNA1D mutation was the most common genetic cause of APN (20/39 with successful sequencing, 51%). Of the 18 sequenced NFA DNA samples, two had somatic mutations in CTNNB1 (n=1) and GNAS (n=1). Conclusion: APN is the major histologic feature of PA in late adulthood. Co-existence of NFA also appears to be a frequent observation in this age population. Somatic CACNA1D and KCNJ5 mutations are common in APN and APA, respectively. Presentation: Friday, June 16, 2023
THU606 Cognitive Impairment In Patients With Mild Autonomous Cortisol Secretion: A Cross-sectional Study
Nathani, Rohit , Singh, Sumitabh , Thangamuthu, Karthik, Suresh, Malavika, Zhang, Catherine, Thomas, Melinda, Fell, Vanessa , Atkinson, Elizabeth J. , Achenbach, Sara J., Saini, Jasmine , Ebbehøj, Andreas , Stricker, Nikki H. , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.136 Get It

Abstract Disclosure: J. Saini: None. R. Nathani: None. S. Singh: None. K. Thangamuthu: None. M. Suresh: None. C. Zhang: None. A.L. Ebbehøj: None. M. Thomas: None. V. Fell: None. E. Atkinson: None. S. Achenbach: None. N. Stricker: None. I. Bancos: None. Introduction: While patients with overt Cushing syndrome are reported to have impaired cognition, the impact of milder, long-standing hypercortisolism on cognition is incompletely characterized. Objective: To determine the impact of MACS on cognition as compared to age, sex, and education-matched referent subjects. Methods: We conducted a single-center cross-sectional study of adults with MACS and referent subjects. MACS was defined as serum cortisol&gt;1.8 mcg/dL after 1 mg dexamethasone suppression test (DST) in patients with adrenal incidentalomas. Referent subjects were included if they had abdominal imaging and had no adrenal disorders. Exclusion criteria were malignancy and exogenous glucocorticoid use within 1 year. All participants underwent a cognitive evaluation using the NIH Toolbox Cognition Battery between 1/2019 to 7/2022. NIH Toolbox assesses 8 cognitive domains using 7 tests and yields 3 composite scores: fluid cognition (executive function, episodic memory, cognitive flexibility, working memory, and processing speed), crystallized cognition (language and vocabulary), and total composite cognition (composite of all). Results are given in fully corrected T scores (adjusted for age, sex, race, and education) with an average of 50 and a standard deviation (SD) of 10. A subgroup analysis was performed based on DST cortisol. The Kruskal-Wallis test was used to compare scores between groups. Results: A total of 94 patients with MACS (median age 57.2 years, IQR 47.8-66.5, 70% women) and 94 referent subjects (median age 58 years, IQR 49.1-66.4, 70% women) were included. The median post-DST cortisol in patients with MACS was 3.3 mcg/dL (IQR, 2.4-6.2). The mean (SD) total composite T-score was lower in patients with MACS vs referent subjects (51 (9.1) vs 56.3 (9.3), P&lt;0.001). Patients with MACS demonstrated lower mean fluid composite T-score when compared to referent subjects (49.5 (10.4) vs 56.9 (9.7), P&lt;0.001). However, mean crystallized composite T-scores were similar in patients with MACS and referent subjects (52.3 (8.1) vs 53.9 (9.6), P=0.342). A subgroup analysis of patients with post-DST cortisol &lt;3 mcg/dL (n=40) vs patients with post-DST cortisol &gt;3 mcg/dL (n=54) did not show any differences in the total, fluid, or crystalized composite scores. Conclusion: Patients with MACS demonstrate lower cognitive performances than a referent group suggesting MACS has a subtle impact on cognitive functioning. The pattern of cognitive impairment in patients with MACS is similar to that seen with normal cognitive aging: impaired fluid cognitions and unaffected crystallized cognition). Cognitive performance did not differ based on the degree of MACS suggesting that in the absence of overt features of hypercortisolism, the degree of MACS is less important than the presence of MACS. Presentation: Thursday, June 15, 2023